Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rHSV 1 APD1

Next Previous
X
Search
Drug Profile

rHSV 1 APD1

Alternative Names: Recombinant Human PD-1 Antibody Herpes Simplex virus - Zhejiang Yangshengtang Biotech; Recombinant PD-1 antibody - Zhejiang Yangshengtang Biotech; rHSV-1-APD1

Latest Information Update: 28 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Yangshengtang Biotech Co., Ltd.
  • Class Antibodies; Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, In adults) in China (Intratumoural, Injection)
  • 28 Jan 2023 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, In adults) in China (IV, Injection)
  • 01 Dec 2019 Phase-I clinical trials in Solid tumours (In the elderly, Late-stage disease, In adults) in China (Intratumoural) (ChiCTR1900027322)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top